Price
No data yet.
Social Signal Score
Analyst Ratings
17 analystsRevenue
$14.27M+1591.23%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Dennis Lanfear
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 145
- Beta
- 1.03
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -14.13
Financials
Revenue
$14.27M+1591.2%Net Income
$-39.33MEBITDA
$-35.24MFree Cash Flow
$-34.02MEPS (diluted)
$-0.25Shares Outstanding (diluted)
154.97M+249.5%Operating Expenses
$43.83MCash & Debt
$83.63MReturn of Capital
$0.00Revenue by Segment (annual)
$1.34MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $42.17M | $-170.29M | $-1.45 |
| 2024 | $266.96M | $28.51M | $0.25 |
| 2023 | $257.24M | $-237.89M | $-2.53 |
| 2022 | $211.04M | $-291.75M | $-3.76 |
| 2021 | $326.55M | $-287.10M | $-3.81 |
| 2020 | $475.82M | $132.24M | $1.85 |
| 2019 | $356.07M | $89.83M | $1.29 |
| 2018 | $1.56M | $-209.34M | $-3.22 |
| 2017 | $1.56M | $-238.17M | $-4.48 |
| 2016 | $190.11M | $-127.34M | $-3.04 |
| 2015 | $30.04M | $-223.26M | $-6.01 |
| 2014 | $31.11M | $-87.13M | $-10.64 |
| 2013 | $2.75M | $-53.63M | $-2.97 |
| 2012 | $1.90M | $-33.02M | $-11.69 |
Valuation
CHRShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
57+88.89%Social Signal Score
Mentions (15)
- Newszacks.com·4d ago·Neutral
Here's Why Coherus Oncology (CHRS) Is a Great 'Buy the Bottom' Stock Now Coherus Oncology (CHRS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
View source ↗ - Newszacks.com·9d ago·Neutral
Down 49.7% in 4 Weeks, Here's Why Coherus Oncology (CHRS) Looks Ripe for a Turnaround The heavy selling pressure might have exhausted for Coherus Oncology (CHRS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
View source ↗ - Newsfool.com·12d ago·Neutral
Coherus Oncology: 3 Key Takeaways for Long-Term Investors Coherus Oncology is cutting headcount by 30% to reduce quarterly costs. Tagmokitug development will focus on second-line esophageal cancer treatment.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Coherus Oncology, Inc. (CHRS) Q3 2026 Earnings Call Transcript Coherus Oncology, Inc. ( CHRS ) Q3 2026 Earnings Call November 9, 2026 5:00 PM EST Company Participants Carrie Graham - Vice President of Investor Relations & Advocacy Dennis Lanfear - Chairman, President & CEO Rosh Dias - Chief Medical Officer Sameer Goregaoker - Chief Commercial Officer Bryan McMichael - Chief Financial Officer Theresa Lavallee - Chief Development Officer & Chairman of Scientific Advisory Board Conference Call Part…
View source ↗ - Newsmarketbeat.com·13d ago·Negative
What Coherus Oncology (CHRS) Said on Its Q3 Earnings Call Coherus Oncology NASDAQ: CHRS plans to cut approximately 30% of its workforce and focus development of its experimental drug tagmokitug on esophageal cancer as it seeks to reduce spending and grow sales of its cancer treatment LOQTORZI.
View source ↗ - Newszacks.com·13d ago·Negative
Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates Coherus Oncology (CHRS) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.33 per share a year ago.
View source ↗ - Newszacks.com·20d ago·Neutral
Will Coherus Oncology (CHRS) Report Negative Earnings Next Week? What You Should Know Coherus Oncology (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newsmarketbeat.com·25d ago·Negative
Coherus Oncology Reports 89% Response Rate in Early ESCC Study Coherus Oncology NASDAQ: CHRS presented interim clinical data for tagmokitug, an investigational therapy designed to target CCR8-positive regulatory T cells, in several solid-tumor settings. The company highlighted early activity in esophageal squamous cell carcinoma, or ESCC, and said it plans to expand cohorts and discuss potential regulatory paths with the U.S. Food and Drug Administration.
View source ↗ - Newsglobenewswire.com·25d ago·Neutral
…orts continued development- - Company to host a webcast today at 4:30 pm EDT- REDWOOD CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) today announced interim clinical data from the TREGCHECK™ development program evaluating tagmokitug, its investigational cytolytic CCR8 antibody, in combination with toripalimab, with or without chemotherapy.
View source ↗ - Newsglobenewswire.com·26d ago·Negative
Coherus to Participate in Upcoming Investor Conferences REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be webcasting its participation in the following upcoming investor conferences:
View source ↗ - Newsglobenewswire.com·27d ago·Negative
Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026 REDWOOD CITY, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2026 financial results will be released on Monday, November 9, 2026. Starting at 5:00 p.m. Eastern Daylight Time on November 9, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.
View source ↗ - Newsglobenewswire.com·39d ago·Neutral
…Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026 REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) today announced that the Company will release interim clinical data related to its tagmokitug development program evaluating the cytolytic CCR8 antibody with toripalimab and multiple solid tumors on Wednesday, October 28, 2026. Coherus management will host a webcast from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time to discuss …
View source ↗ - Newsseekingalpha.com·67d ago·Positive
Coherus Oncology, Inc. (CHRS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Coherus Oncology, Inc. (CHRS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·83d ago·Negative
Coherus to Participate in Upcoming Investor Conferences REDWOOD CITY, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be participating in upcoming investor conferences:
View source ↗ - Newsglobenewswire.com·97d ago·Negative
…oherus Oncology into a fully integrated, innovative immuno-oncology company – REDWOOD CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) (“Coherus”, “Coherus Oncology” or the “Company”) today announced a special dividend of contingent value rights (each, a “CVR” and collectively, the “CVRs”), which will be distributed on a pro rata basis to stockholders of record of the Company's common stock as of 5:00 p.m.
View source ↗
Earnings
Mon, Mar 8(in 4 months)
Consensus estimate $-0.19 per share
Typical surprise -3.1% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 9$-0.25 vs $-0.22miss
- Wed, Aug 5$-0.19 vs $-0.25beat
- Mon, May 11$-0.25 vs $-0.26beat
- Mon, Mar 9$-0.34 vs $-0.36beat
- Thu, Nov 6$-0.33 vs $-0.32miss
- Thu, Aug 7$-0.34 vs $-0.31miss
Estimates and results for CHRS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CHRS officers and directors.
- Bought
- —
- Sold
- $524k
0 trades
2 trades
- Wahlstrom Matssold
- Lanfear Dennis Msold
98 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CHRS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
